Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    mdx-1106 hcv
Show Display Options
Rank Status Study
1 Completed A Study of MDX-1106 to Treat Patients With Hepatitis C Infection
Condition: Hepatitis C
Interventions: Drug: MDX1106-02;   Drug: Placebo
2 Recruiting Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)
Condition: Hepatocellular Carcinoma
Intervention: Biological: Nivolumab

Indicates status has not been verified in more than two years